Agreement - October 23, 2025
Medivir enters licensing agreement with Biossil
Medivir has entered into an exclusive licensing agreement, through which Biossil, Inc. will receive global, exclusive development rights for remetinostat, a clinical-stage topical HDAC inhibitor.
Agreement - September 25, 2025
Evaxion out-licenses vaccine candidate to MSD
Evaxion has out-licensed its vaccine candidate EVX-B3 to MSD as per the option and license agreement entered between the two companies in September 2024.
Agreement - September 17, 2025
ALK enters partnership with GenSci
ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.
Agreement - August 26, 2025
BioArctic and Novartis sign agreement – an upfront payment of USD 30 million
The company has entered into an option, collaboration and license agreement with Novartis Pharma regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed target in neurodegeneration.
Agreement - August 11, 2025
Sever Pharma Solutions expands partnership with Silo Pharma
Under the new agreement, Sever Pharma Solutions will scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia.
Agreement - August 11, 2025
Nanexa signs agreement with major pharma company
The company has announced the signing of an extension of a feasibility agreement with a major pharmaceutical company to investigate the use of Nanexa's PharmaShell platform for a specific drug with current yearly sales exceeding USD 1 billion.
